Furthermore, Chong et al. propose that PD-1 blockade with ICIs may still provide benefits for some patients with B-cell lymphomas who exhibit resistance to primary CAR T-cell therapy [21]. The gene discussed is PDCD1; the disease is B-cell non-Hodgkin lymphoma.